Neuro3d Receives Support from ANVAR for Ongoing Clinical Development of its Antidepressant
Neuro3d, a biopharmaceutical company focused on drug discovery and development for psychiatric disorders, announced today that ANVAR, the French Agency for Innovation, has provided the company EUR900,000 funding to support further clinical development of the phosphodiesterase-4 inhibitor ND1251 as a potential treatment of depression. This amount is in addition to the earlier strong financial support for the preclinical development of ND1251 and the phase I development of ocaperidone. Funding from ANVAR is granted following a rigorous selection process by their local office representatives.
"The strong support from ANVAR highlights the quality of our research. We would like to thank ANVAR, in particular the Alsace regional office, for their continued commitment to our research in finding new treatments for people with psychiatric disorders, in this case depression. We look forward to continuing our successful collaboration," commented Charles Woler, CEO of Neuro3d.
Phase I trials with ND1251 were recently initiated to establish the safety, tolerability and pharmacokinetics, as well as to demonstrate activity in the brain. ND1251 is a very potent compound with a large therapeutic window. In animal models, it does not exhibit the typical side effects, such as emesis and sedation that prevented the clinical use of previously developed PDE4 inhibitors. ND1251 also possesses a good safety profile showing no prohibitive effects on respiratory, cardiac or CNS parameters. In preclinical studies, ND1251 has shown anti-depressant, memory enhancing and anti-inflammatory effects. On the basis of these activities ND1251 may also have applications in other CNS disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis.
The main mission of ANVAR is to support the innovation of entrepreneurs, small and medium enterprise and industry, and research laboratories. The funding available from ANVAR allows innovators to continue with projects while at the same time, spreading the financial risk. ANVAR provides a range of support activities, in addition to potential funding, to help further develop innovation in France.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
